Propuesta de Supply Chain Management y logística para la empresa Madecentro Colombia S.A.S.

El grupo colaborativo 207115_31 de este Diplomado de profundización en Supply Chain Management y logística como opción de grado del periodo 1602 de 2023, decidió de manera equitativa trabajar en la propuesta de su implementación en la empresa Madecentro Colombia S.A.S. Antiguamente la forma de direccionar los procesos que requería una empresa no tenían como tal un nombre o un dominio, hoy en día ya existe otra forma de ver y orientar a una compañía, aunque muchas veces existe una confusión de conceptos en cuanto a logística y SCM, la logística es aquella que se encarga de coordinar los procesos relacionados con la distribución de la mercancía y es parte de Supply Chain Management, claramente la logística es un pilar fundamental dentro de SCM, porque sin ella no existiría el control necesario en cada uno de los componentes de una cadena de suministro. Supply Chain Management es un proyecto dentro de una empresa que reúne los aspectos más relevantes de está buscando la mejor forma de planificar y desarrollar procesos que conlleven al éxito de la misma, por ello es que Supply Chain es mucho más que logística de una organización sino que esta aporta una cadena de valor a los procesos orientados, la gestión de una cadena de suministro debe estar presente en cada uno de los departamentos de una empresa, comenzando por la gerencia, continuando con administración, contabilidad, compras, marketing, producción, almacén, distribución y servicios de postventa entre otros, su aplicación puede ser muy favorable a la hora de la respectiva toma de decisiones. La elección de la empresa Madecentro fue unánime, todos los participantes del grupo estuvimos de acuerdo en trabajar en esta compañía, ya que esta es un empresa Colombiana, del sector de la manufactura y cuya actividad económica se basa en la fabricación y distribución de artículos de madera, la cual tiene varias sedes y puntos de venta en diferentes ciudades del país, lo cual era propicio para una posible visita presencial, se espera la consolidación de la mayor información posible que se pueda reunir y con ayuda de contenidos bibliográficos poder plasmar las ideas y compactar mejor la propuesta de logística y Supply Chain en Madecentro. El propósito de este proyecto tiene como finalidad el desglose de cada uno de los aspectos que componen a Madecentro Colombia S.A.S, para que de manera detallada se analice la situación actual y de manera argumentativa proponer algunos cambios o soluciones que serían de gran impacto para la mejora de los procesos logísticos, encontramos que Madecentro es una compañía que está muy bien direccionada ya que su crecimiento ha sido bastante, tiene gran cantidad de clientes fieles lo cual permite que esta se posicione en un alto nivel en el mercado, algo que destaca en la compañía es la fabricación de productos bajo pedido y por diseño del cliente lo cual hace que los artículos sean totalmente personalizados. Esta propuesta de Supply Chain Management y Logística en la empresa Madecentro Colombia S.A.S está compuesto por 12 capítulos en donde el grupo colaborativo propone nuevas estrategias e ideas que complementan cada uno de los aspectos que componen una cadena de suministro, estos temas están relacionados básicamente a las mejores prácticas tales son: estructura de la red, aprovisionamiento, almacenamiento, distribución, gestión de inventarios, posición logística de Colombia en el mercado, mega tendencias de SCM y Logística. La realización de este proyecto fue muy satisfactorio para todos los participantes ya que en este trabajo están plasmados todos los conocimientos que adquirimos durante la carrera, especialmente la gestión de cadenas de suministro y logística.The collaborative group 207115_31 of this Deepening Diploma in Supply Chain Management and Logistics as a degree option for period 1602 of 2023, decided equally to work on the proposal for its implementation in the company Madecentro Colombia S.A.S. In the past, the way of directing the processes that a company required did not have a name or a domain as such, today there is another way of seeing and guiding a company, although many times there is a confusion of concepts in terms of logistics and SCM , logistics is the one that is in charge of coordinating the processes related to the distribution of merchandise and is part of Supply Chain Management, clearly logistics is a fundamental pillar within SCM, because without it the necessary control would not exist in each of the components of a supply chain. Supply Chain Management is a project within a company that brings together the most relevant aspects of looking for the best way to plan and develop processes that lead to its success, which is why Supply Chain is much more than logistics of an organization but rather Since it provides a value chain to the oriented processes, the management of a supply chain must be present in each of the departments of a company, beginning with management, continuing with administration, accounting, purchasing, marketing, production, warehouse , distribution and after-sales services among others, its application can be very favorable at the time of the respective decision-making. The choice of the Madecentro company was unanimous, all the group participants agreed to work in this company, since this is a Colombian company, in the manufacturing sector and whose economic activity is based on the manufacture and distribution of articles of madera, which has several offices and points of sale in different cities of the country, which was propitious for a possible face-to-face visit, the consolidation of the greatest possible information that can be gathered is expected and with the help of bibliographic contents

How do women living with HIV experience menopause? Menopausal symptoms, anxiety and depression according to reproductive age in a multicenter cohort

CatedresBackground: To estimate the prevalence and severity of menopausal symptoms and anxiety/depression and to assess the differences according to menopausal status among women living with HIV aged 45-60 years from the cohort of Spanish HIV/AIDS Research Network (CoRIS). Methods: Women were interviewed by phone between September 2017 and December 2018 to determine whether they had experienced menopausal symptoms and anxiety/depression. The Menopause Rating Scale was used to evaluate the prevalence and severity of symptoms related to menopause in three subscales: somatic, psychologic and urogenital; and the 4-item Patient Health Questionnaire was used for anxiety/depression. Logistic regression models were used to estimate odds ratios (ORs) of association between menopausal status, and other potential risk factors, the presence and severity of somatic, psychological and urogenital symptoms and of anxiety/depression. Results: Of 251 women included, 137 (54.6%) were post-, 70 (27.9%) peri- and 44 (17.5%) pre-menopausal, respectively. Median age of onset menopause was 48 years (IQR 45-50). The proportions of pre-, peri- and post-menopausal women who had experienced any menopausal symptoms were 45.5%, 60.0% and 66.4%, respectively. Both peri- and post-menopause were associated with a higher likelihood of having somatic symptoms (aOR 3.01; 95% CI 1.38-6.55 and 2.63; 1.44-4.81, respectively), while post-menopause increased the likelihood of having psychological (2.16; 1.13-4.14) and urogenital symptoms (2.54; 1.42-4.85). By other hand, post-menopausal women had a statistically significant five-fold increase in the likelihood of presenting severe urogenital symptoms than pre-menopausal women (4.90; 1.74-13.84). No significant differences by menopausal status were found for anxiety/depression. Joint/muscle problems, exhaustion and sleeping disorders were the most commonly reported symptoms among all women. Differences in the prevalences of vaginal dryness (p = 0.002), joint/muscle complaints (p = 0.032), and sweating/flush (p = 0.032) were found among the three groups. Conclusions: Women living with HIV experienced a wide variety of menopausal symptoms, some of them initiated before women had any menstrual irregularity. We found a higher likelihood of somatic symptoms in peri- and post-menopausal women, while a higher likelihood of psychological and urogenital symptoms was found in post-menopausal women. Most somatic symptoms were of low or moderate severity, probably due to the good clinical and immunological situation of these women

Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials

Abstract Background Convalescent plasma has been widely used to treat COVID-19 and is under investigation in numerous randomized clinical trials, but results are publicly available only for a small number of trials. The objective of this study was to assess the benefits of convalescent plasma treatment compared to placebo or no treatment and all-cause mortality in patients with COVID-19, using data from all available randomized clinical trials, including unpublished and ongoing trials (Open Science Framework, https://doi.org/10.17605/OSF.IO/GEHFX ). Methods In this collaborative systematic review and meta-analysis, clinical trial registries (ClinicalTrials.gov, WHO International Clinical Trials Registry Platform), the Cochrane COVID-19 register, the LOVE database, and PubMed were searched until April 8, 2021. Investigators of trials registered by March 1, 2021, without published results were contacted via email. Eligible were ongoing, discontinued and completed randomized clinical trials that compared convalescent plasma with placebo or no treatment in COVID-19 patients, regardless of setting or treatment schedule. Aggregated mortality data were extracted from publications or provided by investigators of unpublished trials and combined using the Hartung–Knapp–Sidik–Jonkman random effects model. We investigated the contribution of unpublished trials to the overall evidence. Results A total of 16,477 patients were included in 33 trials (20 unpublished with 3190 patients, 13 published with 13,287 patients). 32 trials enrolled only hospitalized patients (including 3 with only intensive care unit patients). Risk of bias was low for 29/33 trials. Of 8495 patients who received convalescent plasma, 1997 died (23%), and of 7982 control patients, 1952 died (24%). The combined risk ratio for all-cause mortality was 0.97 (95% confidence interval: 0.92; 1.02) with between-study heterogeneity not beyond chance (I2 = 0%). The RECOVERY trial had 69.8% and the unpublished evidence 25.3% of the weight in the meta-analysis. Conclusions Convalescent plasma treatment of patients with COVID-19 did not reduce all-cause mortality. These results provide strong evidence that convalescent plasma treatment for patients with COVID-19 should not be used outside of randomized trials. Evidence synthesis from collaborations among trial investigators can inform both evidence generation and evidence application in patient care

Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)

In 2008, we published the first set of guidelines for standardizing research in autophagy. Since then, this topic has received increasing attention, and many scientists have entered the field. Our knowledge base and relevant new technologies have also been expanding. Thus, it is important to formulate on a regular basis updated guidelines for monitoring autophagy in different organisms. Despite numerous reviews, there continues to be confusion regarding acceptable methods to evaluate autophagy, especially in multicellular eukaryotes. Here, we present a set of guidelines for investigators to select and interpret methods to examine autophagy and related processes, and for reviewers to provide realistic and reasonable critiques of reports that are focused on these processes. These guidelines are not meant to be a dogmatic set of rules, because the appropriateness of any assay largely depends on the question being asked and the system being used. Moreover, no individual assay is perfect for every situation, calling for the use of multiple techniques to properly monitor autophagy in each experimental setting. Finally, several core components of the autophagy machinery have been implicated in distinct autophagic processes (canonical and noncanonical autophagy), implying that genetic approaches to block autophagy should rely on targeting two or more autophagy-related genes that ideally participate in distinct steps of the pathway. Along similar lines, because multiple proteins involved in autophagy also regulate other cellular pathways including apoptosis, not all of them can be used as a specific marker for bona fide autophagic responses. Here, we critically discuss current methods of assessing autophagy and the information they can, or cannot, provide. Our ultimate goal is to encourage intellectual and technical innovation in the field